Insilico Medicine Inc. has reported new NLRP3 inflammasome inhibitors potentially useful for the treatment of obesity, autoimmune and autoinflammatory diseases.
Ascletis Pharma (China) Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, hyperlipidemia, fibrosis, hepatic steatosis, thyroid cancer and hypercholesterolemia, among others.
Hyperuricemia is defined as elevated uric acid levels in serum, usually exceeding 6.8 mg/dL, and the primary pathological cause of gout. Chinese investigators have reported recent results on the urate transporter 1 (URAT1) inhibitor HYJ-2 for the potential treatment of hyperuricemia.
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions and cell types. Scientists at the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) used single-cell sequencing and unveiled distinct gene expression patterns regulated by hormones and sex chromosomes. This detailed map of the brain’s molecular biology shows how women and men switch on and off more than 3,000 brain genes differently and expands the catalogue of X chromosome genes that escape inactivation.
Corbus Pharmaceuticals Inc. has divulged new cannabinoid CB1 receptor antagonists or inverse agonists potentially useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.
Neurocrine Biosciences Inc. has discovered new peptides acting as corticotropin-releasing factor CRF2 receptor agonists potentially useful for the treatment of obesity.
There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30.
Chengdu Diao Pharmaceutical Group Co. Ltd. has patented new 1,2,4-triazole compounds characterized as apelin receptor (APLNR) agonists. As such, they are described as useful for the treatment of obesity, hypertension, pulmonary hypertension, heart failure, diabetes, atherosclerosis, osteoporosis and sarcopenia.
The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is interpersonal variability in efficacy of these medications for weight loss, as well as in the incidence of undesired side effects. Investigators from the 23andMe Research Institute have shed some light on how variations in the GLP-1R and GIP receptor (GIPR) genes impact their effectiveness and the occurrence of side effects.
RSS
